“2018 has so far been another gangbuster year for biotech IPOs: the first three quarters of the year have delivered nearly 50 new biotech offerings, reinforcing the strong new issuance performance of the past 6 years.

With lots of pundits raising concerns about the market overheating with positivity on good days, or over-selling negativity on bad days, it’s worth reflecting on how the data this year actually matches up in terms of post-IPO share performance versus prior years.”

Text and Images ©2018 LifeSciVC.com